Background: Although the main causative genes for hereditary multiple exostoses (HME) are EXT-1 and EXT-2, there are still many HME patients without EXT-1 and EXT-2 mutations. This study aimed to identify novel candidate genes for the development of HME in patients without EXT-1 and EXT-2 mutations.
Background
Hereditary multiple exostoses (HME) are autosomal dominant inheritance diseases in children, with an incidence of 1/50000 (Beltrami et al. 2016) . The clinical manifestation of HME varies, and the most commonly involved bones include the distal femur, proximal tibia, fibula, and humerus (Beltrami et al. 2016; Mcfarlane et al. 2016; Pacifici 2017) .
At present, the detailed mechanism of HME is still unclear. Many studies have found that the development of HME is associated with gene mutations in exostosin-1 (EXT-1) and exostosin-2 (EXT-2) (Wuyts and Van Hul 2000; Jennes et al. 2009; Jochmann et al. 2014; Yang et al. 2019b ). The EXT gene encodes a protein product of the enzyme glycosyltransferase, which plays an important role in the synthesis of heparan sulfate proteoglycans (HSPGs). As an important component of the extracellular matrix (ECM), HSPG regulates the proliferation and differentiation of chondrocytes (Jochmann et al. 2014 ). The synthesis defect of HSPG due to mutations of EXT-1 or EXT-2 gives rise to abnormal proliferation and differentiation of chondrocytes and subsequently leads to the development of HME.
Although the main causative gene for HME is EXT-1 and EXT-2 (Wuyts and Van Hul 2000; Heinritz et al. 2009; Jennes et al. 2009 ), there are still many HME patients without EXT-1 and EXT-2 gene mutations (Ishimaru et al. 2016; Santos et al. 2018) . Thus, it is meaningful to identify other candidate genes in patients with HME. However, few genetic studies have focused on HME patients without EXT-1 and EXT-2 mutations.
In the present study, we performed whole-exome sequencing in a typical Chinese HME family without EXT-1 and EXT-2 mutations. The aim of this study was to identify novel candidate genes for the development of HME.
Materials And Methods

Subjects
The subjects in this study were from a family in GuangDong Province, China. The proband (4 years, male) sought medical advice in our hospital because of multiple exostoses at the bilateral distal femur, proximal tibia and fibula, distal tibia, proximal humerus, and left scapula ( Figure 1) .
The parents were also evaluated by medical record review, physical examination, and history taking to obtain detailed information about all the family members. As a result, the mother and grandfather of the proband were also diagnosed with HME ( Figure 2 ). The great-grandfather of the proband was also reported to have multiple exostoses, although we could not perform physical examination to confirm this information.
The study protocol was approved by the Human Ethics Committee of the GuangZhou Women and Children 's Medical Center and GuangZhou Medical University (NO. 2017-320) .
All patients signed informed consents.
Library construction and whole-exome sequencing and data analysis
Genomic DNA was extracted from peripheral blood samples, and the DNA concentration was detected by a Qubit Fluorometer. Sample integrity and purity were detected by agarose gel electrophoresis. Exons of EXT-1 and EXT-2 were sequenced by the Guangzhou Institute of Pediatrics in our hospital via Sanger sequencing to identify whether the family had mutations in the already established HME-associated causal genes; however, no mutations were found in these genes. Thus, the results suggested that unknown mutations may be responsible for the development of HME in this family. Therefore, whole-exome sequencing was subsequently performed in this family.
All the processes of whole-exome sequencing were performed in The Beijing Genomics Institute (BGI)-Shenzhen (Shenzhen, China). In brief, genomic DNA was randomly fragmented to an average size of 250-300 bp a Covaris s220 (Covaris, USA) sonication machine. Fragmented DNAs were tested by agarose gel electrophoresis and purified with the AxyPrep Mag PCR Clean Kit (Axygen, USA). The selected fragments were subjected to end-repair, 3' adenylation, adaptor ligation, and PCR amplification, and the PCR products were recovered by the AxyPrep Mag PCR Clean Kit. Then, the library was qualified by the Agilent Technologies 2100 Bioanalyzer and ABI StepOnePlus Real-Time PCR System. The qualified libraries were sequenced on the Illumina HiSeq Xten System (BGI-ShenZhen, China) with 150 bp end reads. The sequencing image data were then translated to primary raw reads (paired-end reads) using Illumina Base Calling software. The human reference genome assembly hg19 (GRCh37) was used as a reference sequence in this analysis process.
The detection of variants was performed by the Genome Analysis Toolkit (GATK v3.3.0, Broad Institute), and all the variants were saved as a variant call format (VCF) file.
Tertiary analysis was performed based on VCF files from the secondary analysis, including quality filtering, annotation, data aggregation, and functional prediction. Three databases (RefGene, KnownGene, and Ensembl) were used to annotate these variations. All variants were filtered if the variant was annotated as nonsynonymous, frameshift, or splicing mutation in one of these three databases.
Variant Validations
Candidate variants from whole-exome sequencing were validated by Sanger sequencing.
Results
Whole-exome sequencing
All samples from the family were successfully sequenced, and variants were detected with an average sequencing depth on the target over 100 and 98% coverage of the target region. The high-quality reads obtained from II-5, II-6, II-7, III-2, III-3, III-4, and the proband (IV-1) were 6858 Mb, 5668 Mb, 5516 Mb, 5917 Mb, 6049 Mb, 5989 Mb, and 5560 Mb, respectively. VCF files for samples in the family were imported together into SnpEff software for posterior annotation and filtering. According to the phenotype of the family, there are two potential types of inheritance models in this family, including autosomal dominant inheritance and autosomal recessive inheritance.
Under the autosomal dominant inheritance model, the patient had a heterozygous mutation, and the normal subject had no variant. We used three databases, including refGene, KnownGene, and Ensembl, to annotate all the variants. As a result, a total of 1830 original variants were revealed to be heterozygous mutations in the three patients suffering from HME and not in the healthy controls (Supplementary data 1-autosomal_dominant.vcf). Of these variants, 182 mutations were nonsynonymous mutations. If we excluded the mutations located at repeating regions of the genome, there were 145 mutations left. Then, there were 28 mutations left when we excluded the variants with mutation frequencies larger than 1% in the Asian population (The 1000
Genomes Project and the Exome Aggregation Consortium database). Among these 28 variants, two variants did not result in amino acid polymorphisms. Further harmful prediction was performed for these 26 mutations using common prediction tools (SIFT, Polyphen2, GERP++, LRT, MutationTaster) (Table 1) , and the mutations that were predicted to be harmful by at least three of these tools and that had no benign prediction were screened out. Finally, there were only two mutations left (c.C1849T in SLC20A2 and c.G506A in LETM1). Both of them were nonsynonymous SNV mutations and were selected as the candidate variant.
Under the autosomal recessive inheritance model, the patient had homozygous mutations, and normal subjects had heterozygous mutations or no mutations. We used three databases, including refGene, KnownGene, and Ensembl, to annotate all the variants. As a result, a total of 246 original variants were revealed to be consistent with this recessive inheritance model (Supplementary data 2-autosomal_recessive.vcf). Of these variants, 19 mutations were nonsynonymous mutations and were not located in repeating regions of the genome. However, all 19 of these variants were excluded due to the mutation frequency larger than 1% in the Asian population (The 1000 Genomes and the Exome Aggregation Consortium database). Further harmful prediction using common prediction tools also screened out no variant.
Variant Validations by Sanger sequencing
The selected candidate variants (c.C1849T in SLC20A2 and c.G506A in LETM1) were then validated by Sanger sequencing. Sanger sequencing results confirmed that these two mutations were present in all patients with HME (II-5, III-4, and IV-1), and other family members did not have these mutations (Figure 3 and Figure 4 ).
Discussion
Mutations in the EXT-1 and EXT-2 genes are considered to be the main cause of HME (Wuyts and Van Hul 2000; Jennes et al. 2009 ). Many studies have identified many mutation sites in EXT-1 and EXT-2 (Xia et al. 2016; Guo et al. 2019; Yang et al. 2019a ).
The prevalence of EXT-1 and EXT-2 gene mutations is 47.2%-95.7% in patients with HME (Xu et al. 1999; Francannet et al. 2001; Vink et al. 2005; Wuyts et al. 2005; Lonie et al. 2006; Jennes et al. 2008; Kojima et al. 2008; Heinritz et al. 2009; Kang et al. 2012; Sarrion et al. 2013; Jamsheer et al. 2014; Ishimaru et al. 2016; Li et al. 2018; Santos et al. 2018 ).
Based on the results of previous studies, the overall positive rate of EXT-1 and EXT-2 mutations is 76.8% in patients with HME; 23.2% of living patients with HME have no EXT-1 or EXT-2 mutation (Table 2) . At present, few studies have focused on HME patients without EXT-1 and EXT-2 mutations. Thus, it is meaningful to identify novel candidate genes in patients with HME.
Our present study revealed a novel mutation (c.C1849T) in SLC20A2 (solute carrier family 20 member 2) to be deleterious by SIFT, PolyPhe2, LRT, GERP++ and MutationTaster database analyses. As a member of the SLC20 family of solute carriers (Collins et al. 2004; Forster et al. 2013) , the SLC20A2 protein comprises 652 amino acids, and the molecular mass is 70392 Da. The SLC20A2 protein (also named Pit-2) is a type III sodium-phosphate (NaPi-III) cotransporter that mediates the transmembrane movement of sodium and phosphate (Solomon et al. 2007; Virkki et al. 2007; Forster et al. 2013) . Pit-2 is expressed on the basolateral membranes of polarized epithelial cells, where they are involved in cellular phosphate homeostasis (Collins et al. 2004) . It is widely expressed in all kinds of tissues and organs, including the kidney and intestine (Collins et al. 2004) . In particular, studies have reported that chondrocytes also express Pit-2 (Solomon et al. 2007; Virkki et al. 2007; Orfanidou et al. 2012 ). In the present study, mutations in SLC20A2 (c.C1849T) led to a change in amino acid (p.R617C), which might induce structural changes and dysfunction of Pit-2, leading to disturbance of phosphate homeostasis in cells. Mutations in SLC20A2 have been reported to be a major cause of primary familial brain calcification (Lemos et al. 2015; Kuroi et al. 2019) . However, the proband in our study did not have brain calcification ( Figure 5 ). Additionally, SLC20A2 is also a physiological regulator of tissue mineralization and plays an important role in the determination of bone quality and strength (Beck-Cormier et al. 2019 ).
SLC20A2 mutation-induced metabolic disturbance of phosphate might be involved in the development of HME. Studies have demonstrated that phosphate plays an important role in regulating the proliferation and differentiation of chondrocytes (Zalutskaya et al. 2009; Khoshniat et al. 2011 ). Zalutskaya et al (Zalutskaya et al. 2009 ) performed investigations in a mouse metatarsal culture model to evaluate the effect of different concentrations of phosphate on endochondral bone formation. They found that a high concentration (7 nM) of phosphate significantly decreased the proliferation of chondrocytes but promoted terminal differentiation of hypertrophic chondrocytes. On the other hand, through a mouse metatarsal culture model, Liu et al (Liu et al. 2014) found that low phosphate concentrations inhibited the differentiation of chondrocytes through the PTHrP signaling pathway. The study of Magne et al (Magne et al. 2003 ) also indicated similar results.
Previous studies have demonstrated that HME is characterized by abnormal proliferation and differentiation of chondrocytes (Milgram 1983; Benoist-Lasselin et al. 2006) . We speculate that SLC20A2 mutation-induced metabolic disorder of phosphate in chondrocytes might lead to abnormal proliferation and differentiation of chondrocytes and subsequently result in the development of HME. LETM1 (leucine zipper and EF-hand containing transmembrane protein 1) mutation (c.G506A) was also predicted to be harmful by common prediction tools. LETM1 encodes a protein that is localized to the inner mitochondrial membrane (Durigon et al. 2018) .
Studies have reported that mutations in this gene cause Wolf-Hirschhorn syndrome (Schlickum et al. 2004; Mcquibban et al. 2010) . At present, there is no relative study about the effect of the LETM1 gene on cartilage and bone. Thus, further studies are needed to evaluate the effect of LETM1 mutation (c.G506A) on the proliferation and differentiation of chondrocytes.
Conclusion
The present study revealed two mutations [SLC20A2 (c.C1849T) and LETM1 (c.G506A) in a Chinese HME family. A mutation in SLC20A2 (c.C1849T) is more likely to be involved in the development of HME. Considering that this is an exploratory study in a family, additional investigations may be required to verify the preliminary results of the present study.
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Figure 5
The cerebral MRI of the proband showed no brain calcification.
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